← Artiva Biotherapeutics, Inc. (ARTV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Artiva Biotherapeutics, Inc. (ARTV)
Biological Products, (No Diagnostic Substances) · market cap $376M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Artiva Biotherapeutics (ARTV) is a small-cap allogeneic NK cell therapy company with 106 employees and a $233M market cap. Its lead asset is an allogeneic NK cell therapy in Phase 2 for refractory rheumatoid arthritis, with a second asset AB-101 in Phase 2 for Non-Hodgkin Lymphoma. The company holds approximately $21M in cash, representing roughly 3 months of runway at current burn rates, making near-term financing a critical concern.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Allogeneic NK Cells | Phase 2 | Refractory Rheumatoid Arthritis (RA) |
| AB-101 | Phase 2 | Non Hodgkin Lymphoma |
Price & technical context
3-month
-29.3%
6-month
+0.6%
12-month
+136.6%
52-wk range
$2.74–$13.39
vs 50-day MA
-33.4%
vs 200-day MA
-13.7%
Realized vol
145.4%
Max drawdown
-90.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARTV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.